Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKIN.L Regulatory News (SKIN)

  • There is currently no data for SKIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cooperative Alliance; Trading Update

21 Jan 2020 07:00

RNS Number : 3838A
Integumen PLC
21 January 2020
 

AIM share code: SKIN

 

21 January 2020

 

Integumen PLC

 

("Integumen" or "Company")

 

Integumen signs cooperative alliance MOU with Innocare Group, Shanghai, China

 

Trading update: Unaudited Revenues up 366% to £1m,

 

 

Integumen's subsidiary Labskin today announces that it has signed a Memorandum of Understanding with Innocare Group. The cooperative alliance has been established to promote innovation and cooperation between research institutions that will assist commercial enterprises in China with routes to regulatory compliance using Labskin and LabskinAI without the need for animal testing for cosmetics and skincare products.

 

Post Year-End 2019 Trading Update:

Even with 6 weeks' delay in opening up the new laboratories in York, UK, demand for Labskin and LabskinAI services mean that following the end of the financial year, Integumen has achieved the 7-figure turnover number (unaudited) we had anticipated. Unaudited figures show that revenues increased 366% to £1.004m (2018: £0.274m - audited) including £0.178m relating to Rinocloud in the period pre-acquisition on 2 May 2019)

 

Gerard Brandon, CEO of Integumen, comments:

"Following a very successful year in 2019, Integumen has started 2020 as the "No.#1 Thought Leader on Skin Microbiome and AI". We have a strong global Top 20 cosmetic and skin care client base and with the signing of this MOU with the Innocare Group, a foothold into the fast-growing Chinese market. Our sales, including recurring revenues, look set to continue strong triple digit growth as our order book of existing and new clients expands across three continents." 

 

Charles Xu, President and CEO of Innocare Group, added:

"We are delighted to be collaborating with Labskin and immediately recognise that our combined expertise, technologies and access to R&D in China and Europe will achieve far more and enable faster commercialisation for our respective technologies on both continents."

 

 

Contacts

 

Integumen plc

Gerard Brandon, CEO

 

+44 (0) 7340 055 648

SPARK Advisory Partners Limited

(Nominated Adviser)

 

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/Zoe Alexander

+44 (0) 20 3657 0050

 

 

About Integumen: www.integumen.com

Integumen is a vertically integrated product and services company for skin related diseases, treatments and therapies with four business units:

 

·; Labskin AI's technology platform incorporates artificial intelligence within clinical research for medical device, pharmaceuticals, cosmeceuticals and related life science test services. Labskin allows skincare, healthcare, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

·; Rinodrive is a data aggregation, refining and AI analysis open-source eco-system designed to provide third-party service providers the ability to offer their clients valuable insights that support clinical, operational and financial decisions in healthcare services, third-level education, government departments and the financial sector.

·; Wound pHase is developing skin and wound care products using its proprietary wound dressing technology. Working in collaboration with CBD providers creating a CBD infused diabetic wound care product range.

·; Stoer-for-men skin products e-commerce division offers a range of skincare products derived from 5 natural super-ingredient plant extracts specifically for men to reduce the signs of ageing and is also used as a control for client testing within Labskin laboratories.

 

 

About the Innocare Group: : (www.labcaregroup.com)

 

Labcare Scientific International, for 10 years, has been a leading scientific instrument, equipment and supplies company serving todays laboratory needs with innovative products from around the world.

 

Partnering with and supporters of the Shanghai Hi-Tech International Development Program, they actively participate internationally to bridge the innovation gap between China and the Rest of the World for technologies in Healthcare, Biotech, Internet of Things.

 

Since 2017 they have participated in the annual European forum "Beyond IoT" held in the Nimbus Research Centre, Cork, Ireland and for the first time Innocare Group will host the "Beyond IoT" Forum in China in 2020.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBMMLTMTJTBJM
Date   Source Headline
28th Apr 20204:37 pmRNSPrice Monitoring Extension
28th Apr 20202:05 pmRNSSecond Price Monitoring Extn
28th Apr 20202:00 pmRNSPrice Monitoring Extension
17th Apr 20202:06 pmRNSSecond Price Monitoring Extn
17th Apr 20202:00 pmRNSPrice Monitoring Extension
30th Mar 20207:00 amRNSUpdate re COVID 19; confirmed orders; investment
23rd Mar 20207:00 amRNSDirector/PDMR Shareholding
18th Mar 202010:22 amRNSDirector/PDMR Shareholding
18th Mar 20207:00 amRNS3 year $3.75m (£3.12m) bacteria prod'n agreement
12th Mar 20202:06 pmRNSSecond Price Monitoring Extn
12th Mar 20202:00 pmRNSPrice Monitoring Extension
26th Feb 20207:00 amRNSLaunch of ecowaterOS; Company Update
7th Feb 20207:00 amRNSIntegumen plc to present at The UK Investor Show
3rd Feb 20207:00 amRNSCommercial & AI partnership with Acumen Software
21st Jan 20207:00 amRNSCooperative Alliance; Trading Update
19th Dec 20197:00 amRNS3-year Rev sharing Framework Ag with Parity Group
16th Dec 20198:43 amRNSDirector/PDMR Shareholdings
9th Dec 201911:05 amRNSPlacing/Subscription to raise £1.368m -replacement
9th Dec 20197:00 amRNSPlacing and subscription to raise £1.368 million
20th Nov 20197:00 amRNSResults of AI water research project
13th Nov 20197:00 amRNSHeads of Terms -Framework Agreement;trading update
7th Nov 20197:00 amRNSMicrobiome and Labskin clone R&D agreements signed
29th Oct 20197:00 amRNSLaunch of ind. Rinodrive AI open-source eco-system
21st Oct 20197:00 amRNSRinocloud subsidiary wins "One To Watch" IT award
8th Oct 201912:34 pmRNSIssue of Equity: Shares in Lieu of Invoice
7th Oct 20197:00 amRNSLabskin signs multi-year service agreement
7th Oct 20197:00 amRNSLabskinAI creates virtual AI psoriasis skin model
11th Sep 20197:00 amRNSInterim Results
5th Sep 20197:00 amRNSLabskin breakthrough clones 16 human skin swabs
2nd Aug 20197:00 amRNSHighlands Nat. Resources agreement with Cellulac
1st Aug 20191:41 pmRNSExercise of Warrants
1st Aug 201911:32 amRNSExercise of Warrants
31st Jul 20194:30 pmRNSResult of AGM
31st Jul 20197:00 amRNSAGM - Trading Update
29th Jul 20197:00 amRNSCollaboration; Expansion of wound care division
19th Jul 20197:00 amRNSLabskinAI:agreementswith global cosmetic companies
12th Jul 20197:00 amRNSChange to interests of a significant shareholder
11th Jul 201910:38 amRNSExercise of Warrants (update)
10th Jul 201912:55 pmRNSExercise of warrants
8th Jul 20197:00 amRNSAGM Notice and Trading Update
28th Jun 20193:03 pmRNSExercise of Warrants
27th Jun 20197:00 amRNSFinal Results
21st Jun 20197:00 amRNSExercise of Warrants
20th Jun 20197:01 amRNSExecutive team and Labskin AI digital hub updates
20th Jun 20197:00 amRNSExercise of Warrants
10th Jun 20197:00 amRNSExercise of Warrant Shares and Call Option Shares
28th May 20197:30 amRNSExercise of Warrants
28th May 20197:00 amRNSNew Labskin AI contracts; additional lab space
21st May 20197:00 amRNSTrading update and Board changes
10th May 201912:19 pmRNSLaunch of Labskin human skin clone tests

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.